Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions
- PMID:32504268
- DOI: 10.1007/s11154-020-09562-9
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions
Abstract
Pituitary adenohypophyseal tumors are considered as benign and termed "adenomas". However, many tumors are invasive and a proportion of these exhibit an "aggressive behavior" with premature death due to progressive growth. Only very rare (0.2%) tumors with metastases are considered malignant and termed "carcinomas". Taking into account this variability in behavior and the oncological definition, pathologists have proposed changing the term adenoma to tumor. Here we explain why use the term tumor instead of adenoma and identify tumor characteristics, associated with a high risk for poor prognosis. In a cohort of 125 tumors with aggressive behavior (APT) and 40 carcinomas with metastases (PC), clinical and pathological features were very similar. The comparison of this cohort (APT+PC) with a reference surgical cohort of 374 unselected patients clearly shows that the two cohorts differ greatly, especially the percentage of tumors with Ki67 ≥ 10% (35%vs3%; p < 0.001). A five-tiered prognostic classification, associating invasion and proliferation, identified grade 2b tumors (invasive and proliferative), with a high risk of recurrence/progression. Because half of the APT+ PC tumors have a Ki67 index ≥10%, and 80% of them show 2 or 3 positive markers of proliferation, we suggest that tumors that are clinically aggressive, invasive and highly proliferative with a Ki67 ≥ 10%, represent tumors with malignant potential. The percentage of grade 2b tumors, suspected of malignancy, which will become aggressive tumors or carcinomas is unknown. It is probably very low, but higher than 0.2% in surgical series. Early identification and active treatment of these aggressive tumors is needed to decrease morbidity and prolong survival.
Keywords: Aggressive pituitary adenoma; Aggressive pituitary tumor; Pituitary adenoma; Pituitary carcinoma; Pituitary tumor.
Similar articles
- Definition and diagnosis of aggressive pituitary tumors.Kasuki L, Raverot G.Kasuki L, et al.Rev Endocr Metab Disord. 2020 Jun;21(2):203-208. doi: 10.1007/s11154-019-09531-x.Rev Endocr Metab Disord. 2020.PMID:31808044Review.
- Refractory pituitary adenoma: a novel classification for pituitary tumors.Dai C, Feng M, Liu X, Ma S, Sun B, Bao X, Yao Y, Deng K, Wang Y, Xing B, Lian W, Zhong D, Ma W, Wang R.Dai C, et al.Oncotarget. 2016 Dec 13;7(50):83657-83668. doi: 10.18632/oncotarget.13274.Oncotarget. 2016.PMID:27845901Free PMC article.
- The epidemiology of aggressive pituitary tumors (and its challenges).Dekkers OM, Karavitaki N, Pereira AM.Dekkers OM, et al.Rev Endocr Metab Disord. 2020 Jun;21(2):209-212. doi: 10.1007/s11154-020-09556-7.Rev Endocr Metab Disord. 2020.PMID:32361816Free PMC article.Review.
- The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.Dai C, Liang S, Sun B, Kang J.Dai C, et al.Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.Front Endocrinol (Lausanne). 2020.PMID:33362722Free PMC article.Review.
- Invasive, atypical and aggressive pituitary adenomas and carcinomas.Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K.Sav A, et al.Endocrinol Metab Clin North Am. 2015 Mar;44(1):99-104. doi: 10.1016/j.ecl.2014.10.008. Epub 2014 Nov 4.Endocrinol Metab Clin North Am. 2015.PMID:25732646Review.
Cited by
- Clinical features of pituitary carcinoma: analysis based on a case report and literature review.Yang Y, Liang W, Fan K, Yang T, Cheng J.Yang Y, et al.Front Endocrinol (Lausanne). 2024 Oct 31;15:1440247. doi: 10.3389/fendo.2024.1440247. eCollection 2024.Front Endocrinol (Lausanne). 2024.PMID:39544231Free PMC article.Review.
- Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.Rak B, Maksymowicz M, Pękul M, Zieliński G.Rak B, et al.Front Endocrinol (Lausanne). 2021 May 31;12:672178. doi: 10.3389/fendo.2021.672178. eCollection 2021.Front Endocrinol (Lausanne). 2021.PMID:34135861Free PMC article.
- Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.Wang X, Dai Y, Lin H, Cheng J, Zhang Y, Cao M, Zhou Y.Wang X, et al.Eur Radiol. 2023 May;33(5):3312-3321. doi: 10.1007/s00330-023-09412-7. Epub 2023 Feb 4.Eur Radiol. 2023.PMID:36738323
- Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas.Cheng J, Sun R, Nie D, Li B, Gui SB, Li CZ, Zhang YZ, Zhao P.Cheng J, et al.Front Surg. 2022 Jun 21;9:923143. doi: 10.3389/fsurg.2022.923143. eCollection 2022.Front Surg. 2022.PMID:35836612Free PMC article.
- Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P.Nie D, et al.Dis Markers. 2021 Aug 16;2021:5300381. doi: 10.1155/2021/5300381. eCollection 2021.Dis Markers. 2021.PMID:34447484Free PMC article.Review.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Medical